BACKGROUND AND OBJECTIVES: To determine whether warfarin prolongs the time to first mechanical-catheter failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a multicenter parallel-group randomized controlled trial with blinding of participants, trial staff, clinical staff, outcome assessors, and data analysts. Randomization was in a 1:1 ratio in blocks of four and was concealed by use of fax to a central pharmacy. Hemodialysis patients with newly-placed catheters receivedlow-intensity monitored-dose warfarin, target international normalized ratio (INR) 1.5 to 1.9, or placebo, adjusted according to schedule of sham INR results. The primary outcome was time to first mechanical-catheter failure (inability to establish a circuit or blood flow less than 200 ml/min). RESULTS: We randomized 174 patients: 87 towarfarin and 87 to placebo. Warfarin was associated with a hazard ratio (HR) of 0.90 (P=0.60; 95% confidence interval [CI], 0.57, 1.38) for time to first mechanical-catheter failure. Secondary analyses were: time to first guidewire exchange or catheter removal for mechanical failure (HR 0.78; 95% CI, 0.37, 1.6); time to catheter removal for mechanical failure (HR 0.67; 95% CI, 0.19, 2.37); and time to catheter removal for any cause (HR 0.89; 95% CI, 0.42, 1.81). Major bleeding occurred in 10 participants assigned to warfarin and seven on placebo (relative risk, 1.43; 95% CI, 0.57, 3.58; P=0.61). CONCLUSIONS: We found no evidence for efficacy of low-intensity, monitored-dose warfarin in preventing mechanical-catheter failure.
RCT Entities:
BACKGROUND AND OBJECTIVES: To determine whether warfarin prolongs the time to first mechanical-catheter failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a multicenter parallel-group randomized controlled trial with blinding of participants, trial staff, clinical staff, outcome assessors, and data analysts. Randomization was in a 1:1 ratio in blocks of four and was concealed by use of fax to a central pharmacy. Hemodialysis patients with newly-placed catheters received low-intensity monitored-dose warfarin, target international normalized ratio (INR) 1.5 to 1.9, or placebo, adjusted according to schedule of sham INR results. The primary outcome was time to first mechanical-catheter failure (inability to establish a circuit or blood flow less than 200 ml/min). RESULTS: We randomized 174 patients: 87 to warfarin and 87 to placebo. Warfarin was associated with a hazard ratio (HR) of 0.90 (P=0.60; 95% confidence interval [CI], 0.57, 1.38) for time to first mechanical-catheter failure. Secondary analyses were: time to first guidewire exchange or catheter removal for mechanical failure (HR 0.78; 95% CI, 0.37, 1.6); time to catheter removal for mechanical failure (HR 0.67; 95% CI, 0.19, 2.37); and time to catheter removal for any cause (HR 0.89; 95% CI, 0.42, 1.81). Major bleeding occurred in 10 participants assigned to warfarin and seven on placebo (relative risk, 1.43; 95% CI, 0.57, 3.58; P=0.61). CONCLUSIONS: We found no evidence for efficacy of low-intensity, monitored-dose warfarin in preventing mechanical-catheter failure.
Authors: A Pierratos; M Ouwendyk; R Francoeur; S Vas; D S Raj; A M Ecclestone; V Langos; R Uldall Journal: J Am Soc Nephrol Date: 1998-05 Impact factor: 10.121
Authors: M A Little; A O'Riordan; B Lucey; M Farrell; M Lee; P J Conlon; J J Walshe Journal: Nephrol Dial Transplant Date: 2001-11 Impact factor: 5.992
Authors: Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent Journal: N Engl J Med Date: 2003-08-14 Impact factor: 91.245
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Ying Wang; Jessica N Ivany; Vlado Perkovic; Martin P Gallagher; Mark Woodward; Meg J Jardine Journal: Cochrane Database Syst Rev Date: 2016-04-04
Authors: Fabio Paglialonga; Andrea Artoni; Simon Braham; Silvia Consolo; Alberto Giannini; Giovanna Chidini; Luisa Napolitano; Ida Martinelli; Giovanni Montini; Alberto Edefonti Journal: Pediatr Nephrol Date: 2015-12-14 Impact factor: 3.714